Plant Part Used


Active Constituents

Terpene lactones (ginkgolides A, B, and C; bilobalide); flavonoids (including myricetin, quercetin, proanthocyanidins, catechins).(1),(2)

[span class=alert]This section is a list of chemical entities identified in this dietary supplement to possess pharmacological activity. This list does not imply that other, yet unidentified, constituents do not influence the pharmacological activity of this dietary supplement nor does it imply that any one constituent possesses greater influence on the overall pharmacological effect of this dietary supplement.[/span]


Ginkgo is among the oldest living species on earth and has been used extensively as a medicinal agent worldwide for centuries. The chemical constituents that have helped ginkgo resist potentially damaging pests during the millennia most certainly contribute to its positive effects on health.(3) Ginkgo is the most frequently prescribed medicinal herb in Europe, with hundreds of studies reporting positive effects from taking ginkgo for both the prevention and treatment of various health complaints. The most dramatic benefits are reported in improving circulation in the elderly.(4),(5) This can lead to enhanced memory, possibly delaying the onset of Alzheimer's disease,(6) reducing senile dementia,(7) tinnitus,(8) and vertigo.(9) Ginkgo’s memory-enhancing effects are reported in younger populations as well.

Interactions and Depletions


Dosage Info

Dosage Range

120-240mg (standardized extract) daily in divided doses.

Most Common Dosage

160mg (standardized extract daily in divided doses.


[span class=doc]Standardization represents the complete body of information and controls that serve to enhance the batch to batch consistency of a botanical product, including but not limited to the presence of a marker compound at a defined level or within a defined range.[/span]

The most current available medical and scientific literature indicates that this dietary supplement should be standardized to 24-32% ginkgo flavoglycosides and 6-12% triterpenes.


Frequently Reported Uses

  • Antioxidant
  • Peripheral Vascular Disease
  • Raynaud's Disease
  • Cerebral Vascular Insufficiency
  • Tinnitus
  • Dementia
  • Memory Enhancement
  • Depression
  • Vertigo
  • Alzheimer's Disease/senile dementia
  • Cognitive Enhancement
  • Improves Microcirculation To The Brain, Heart, Periphery
  • Increases Peripheral Circulation; Cardiovascular Tonic
  • Cardiovascular Support (Angioplasty, Angina, Bypass)

Other Reported Uses

  • Allergies
  • Asthma
  • Hypoxia
  • Impotence
  • Macular Degeneration
  • Arterial Or Venous Insufficiency, Intermittent Claudication
  • Decreases Platelet Aggregation, Improves Blood Flow
  • Increases Cellular Oxygenation
  • Radioprotective
  • Sexual dysfunction
  • Vascular Spasm (Raynaud's)

Toxicities & Precautions


Ginkgo is safe and side effects are extremely rare, but fresh seeds of the ginkgo tree should not be eaten because they may be toxic.


An extremely rare allergic skin reaction has occurred with Ginkgo. (10)

Health Conditions

Based on pharmacology, use with caution in individuals with bleeding disorders. (11)

Side Effects

The most typical side effects are GI distress and headache. These are present in fewer than 0.5 percent of the people in studies.(9)

Cases of subdural hematoma have been reported due to ginkgo use.(12)

Pregnancy/ Breast Feeding

If pregnant or nursing, consult a physician before use.(13),(94)

Age Limitations

Do not use in children under 2 years of age unless recommended by a physician.


Antioxidant Effects

The main active components of ginkgo include the flavoglycosides, and terpene lactones. These compounds act as strong free radical scavengers or antioxidants which can be attributed to many of ginkgo’s positive effect on body systems.(14),(15),(16) Ginkgo’s ability to decrease the loss of cell viability due to oxidative stress in many areas of the body is the main pharmacological property of the therapeutic efficacy of this dietary supplement.(17) Studies have reported that constituents in ginkgo may actually protect the brain neurons from oxidation and subsequent damaging free radicals, decreasing post-ischemic effects, and diseases such as Alzheimer’s disease.(18),(19),(20) It is also postulated that ginkgo’s positive effects against cardiac ischemia-reperfusion injury depend on its antioxidant properties.(21),(22),(23) Also, due to the potent antioxidant activity of ginkgo, a clinical study reported statistically significant improvements in visual function in patients having macular degeneration, glaucoma cataracts, and retinal impairments.(24),(25),(26),(27) Among the many clinical applications of ginkgo as an antioxidant are spinal cord injury,(28) lipid peroxidation pertaining to cholesterol metabolism including protection of HDL,(29),(30) cardiovascular protection including limiting oxidative stress in cardiovascular surgery,(31),(32) hepatoprotective effects,(33),(34) and in general to decrease the mitochondrial oxidative stresses that cause normal aging.(35)

Ginkgo’s antioxidant effects are also reported to decrease the damaging effects of radiation and chemotherapy.(36) The antioxidant activity of ginkgo was reported to decrease the negative effects of clastogenic factors created by radiation exposure.(37) Clastogenic factors are bio-markers of oxidative stress found in the plasma of irradiated persons, either accidentally or therapeutically, and cause the development of latent effects associated with damaging radiation. The negative effects of cyclosporin A on lipid peroxidation in human liver microsomes was decreased with the administration of a standardized ginkgo preparation during in vitro testing, suggesting that ginkgo might be able to prevent radical mediated damage to human membranes caused by this agent.(38) It should be noted that also in this study, vitamin E almost completely inhibited the lipid peroxidation caused by cyclosporin A.

PAF Antagonism

Ginkgo is also reported to inhibit platelet activating factor (PAF), reducing the adhesive nature of platelets possibly through competitive binding.(39) One of the components of ginkgo, ginkgolide B, is a potent platelet-activating factor (PAF) antagonist.(40) This action has been reported to contribute to ginkgo’s influence on increased cerebral and peripheral blood flow, improvement of delivery of nutrients to the brain, oxygenation of the tissues, and its positive effects in asthma and cardiovascular protection.(5),(41),(42) Free radicals and platelet activating factor (PAF) have been implicated as important mediators in neuronal injury after cerebral ischemia-reperfusion and, particularly, in postischemic hypoperfusion.(43) The PAF and antioxidant properties of ginkgo have also been reported useful in acute pancreatitis.(44) Ginkgo may foster vasodilation by stimulating endothelium releasing factor and prostacyclin.(45) It may also stimulate venous tone and improve the clearance of hemotoxins during ischemic episodes.(46)

Senile Dementia and Alzheimer’s Disease  

The efficacy of standardized ginkgo preparations in dementia of the Alzheimer type and multi-infarct dementia has been confirmed by many scientific studies in human subjects (6),(7),(95) although there are conflicting studies.(96),(97),(98),(99) In 1994, a standardized dry extract of ginkgo leaves was approved by German health authorities for the treatment of primary degenerative dementia and vascular dementia.(47) Modern research has helped to provide a better understanding of biochemical events that occur with the disease process of Alzheimer’s, including theories of the accumulation of beta-amyloid (Abeta)-derived peptides and free radical damage in the involvement of the destruction of neuronal cells. (19),(48) Ginkgo has been reported effective in decreasing the toxicity induced by (Abeta)-derived peptides (Abeta25-35, Abeta1-40 and Abeta1-42) on hippocampal primary cultured cells in vitro and also, as stated above, in reducing the damaging oxidative stress to neuronal cells, both of which have been reported to increase the probability of developing senile dementia and Alzheimer’s disease.(49),(50)

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of 309 patients with mild to severe dementia including Alzheimer disease or multi-infarct dementia were placed on a standardized ginkgo preparation or placebo for 52 weeks.(51) From the initial 309 patients included in the study, 202 of these individuals provided data for statistical analysis. Although not as significant as expected, the standardized ginkgo preparation (40mg three times a day) was reported safe and capable of stabilizing and improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. However, a recent 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of 214 subjects with dementia (either Alzheimer’s or vascular dementia) reported that treatment with the same standardized ginkgo preparation as above (either 2 tablets per day, total dosage either 240 or 160mg/day or placebo for a total of 24 weeks) reported no advantage of using the ginkgo extract over placebo.(52)

A study involving healthier individuals also questions the benefit of ginkgo for memory enhancement. This six-week randomized, double-blind, placebo-controlled, parallel-group trial involving 230 individuals older than 60 was designed to evaluate whether ginkgo could improve memory in this patient population. These individuals had to be in good health and needed a baseline Mini-Mental State Examination (MMSE) score greater than 26. They were then randomized to receive ginkgo, 40 mg, 3 times per day or matching placebo, 115 people in each group. Prior to beginning treatment and three days before completion of the six-week treatment program, each patient was evaluated by fifteen standard neuropsychological tests evaluating verbal and nonverbal learning and memory, attention and concentration, and naming and expressive language. Each participant completed a subjective self-report on memory and a companion completed a caregiver clinical global impression of change. The results of this study showed no improvement in the standard neuropsychological tests utilized and there was no difference between the groups in the self-reported memory function or in the global rating completed by their companion.(53)

The efficacy of four commonly used cholinesterase inhibitors (tacrine, donepezil, rivastigmine, metrifonate) and a standardized ginkgo extract were compared for their use in Alzheimer's disease versus placebo.(54) There were no major differences in the four medications and the ginkgo preparation in delaying the symptoms of the progression of dementia. However, tacrine exhibited adverse drug reactions and subsequently a higher drop-out rate. The authors concluded that second-generation cholinesterase inhibitors (donepezil, rivastigmine, metrifonate) and the standardized ginkgo extract should be considered equally effective in the treatment of mild to moderate Alzheimer's dementia.

A 2009 randomized, double-blind exploratory study found that there was no significant difference in the efficiency of Alzheimer’s treatment between a standardized ginkgo supplement and donepezil, with a combination therapy being superior to a mono-therapy with one of both substances.(100) The authors also reported less side effects under a combination therapy of ginkgo and donepezil than under mono-therapy with donepezil.

Using appropriate dosages (240-480mg daily or greater) and standardized supplements are imperative when using ginkgo in AD and senile dementia therapy. It is also important for researchers to follow a more intensive follow-up rather than minimal follow-up of individuals in clinical trials using ginkgo in treating mild-moderate dementia.(101)

General Memory and Learning Impairment

Ginkgo has been reported in laboratory animals to increase learning and other cognitive behaviors.(55),(56),(57) Also, studies in humans have reported positive effects on age-associated memory impairment and learning along with an increase in attention. (52),(58),(59) Although the terpene fraction of ginkgo, which contains the ginkgolides, may contribute to the neuroprotective properties of the leaf, it is also likely that the flavonoid fraction, containing free radical scavengers, is also important in this respect. Taken together, the evidence suggests that Ginkgo biloba extracts are worthy of further investigation as potential neuroprotective agents. Ginkgo may also normalize acetylcholine receptors and, therefore, improve cholinergic function.(60)

A recent 6-week, double-blind, fixed-dose, placebo-controlled, parallel-group experimental study design was conducted to evaluate the effectiveness of ginkgo on cognitive and behavioral functioning.(61) The individuals were given 180 mg of a standardized ginkgo extract or placebo daily for 6 weeks. This group exhibited significantly more improvement on a task assessing speed of processing abilities and memory as compared to participants who received placebo.

Another double blind, placebo controlled, 14 week, parallel group, repeated assessment, multi-center trial of 256 healthy individuals was conducted to evaluate the effectiveness of ginkgo in combination with Panax ginseng (containing 60mg standardized ginkgo and 100mg standardized panax, either 1 capsule twice daily or 2 capsules in the am) on cognitive function.(62) The ginkgo/panax combination was found to significantly improve several different aspects of memory, including working and long-term memory. The memory enhancement was reported throughout the 12-week dosing period and also after a 2-week washout. A small multiple dose, placebo-controlled, double-blind, balanced-crossover study in young healthy subjects found that ginkgo modestly improved memory performance, but acute administration may have a negative effect on the speed of attention task performance, which is opposite to that seen previously following higher doses (greater than 120mg daily standardized).(102)

A 2009 selective review of 29 randomized controlled trials found that here is consistent evidence that chronic administration of ginkgo supplements improves selective attention, some executive processes and long-term memory for verbal and non-verbal material.(103) Also complexation of ginkgo with phosphatidylserine appears to potentiate the cognitive effects.(104)

Intermittent Claudication/ Cardiovascular Effects


Ginkgo has been reported useful in the treatment of peripheral occlusive arterial diseases (PAD).(63) Studies have reported that ginkgo products produce a statistically significant and clinically relevant improvement of the walking performance in patients suffering from intermittent claudication.(64),(65),(66) Ginkgo has been studied and compared to trental, which is used for intermittent claudication and peripheral vascular disturbances.(67) In treadmill walking studies, ginkgo significantly increased pain-free walking distance.(68),(69) Exercising regularly, stopping smoking, and limiting caffeine intake are also important in treating these conditions. Because of its ability to improve blood flow, ginkgo has been used for diabetic neuropathy, circulatory disorders, Raynaud’s Disease (70) or cyanotic, or post-phlebitis pathologies.

A double-blind, placebo-controlled, parallel design trial with a 4-month duration found that in older adults with PAD, ginkgo produced a modest but insignificant increase in maximal treadmill walking time and flow-mediated vasodilation.(105) However, a 2009 Cochrane Database review looked at randomized controlled trials of ginkgo extract, irrespective of dosage, versus placebo in people with intermittent claudication.(106) The authors concluded there is no evidence that ginkgo has a clinically significant benefit for patients with peripheral arterial disease. Further research needs to be performed in this area.

A small randomized trial found that ginkgo was effective in improving vascular endothelial function in early stage diabetic patients through decreasing the plasma level of von Willebrand Factor (vWF), raising the plasma nitric oxide (NO) levels and improving the endothelium dependent vascular dilating function.(107)


Ginkgo has traditionally been used in the treatment of tinnitus with positive results in both human and animal studies.(71),(72) One multicenter, double-blind placebo controlled study of 103 patients with tinnitus reported positive benefits in the condition when using a ginkgo extract.(8) However, some studies have shown contradictory results of ginkgo in the treatment of tinnitus, with no reported value in the condition versus placebo.(73),(74) In these negative studies, three parameters should be taken into consideration that may have prognostic significance: chronicity, periodicity and uni- or bilateral nature of symptoms.(75)


Ginkgo’s use in depression may be in part due to its increase in cerebral blood flow.(76) Ginkgo has been reported in laboratory studies to have monoamine oxidase inhibiting (MAOI) effects (both MAO-A and -B types were inhibited to a similar extent).(77) The authors have postulated that ginkgo’s MAOI ability may be one mechanism for its reported anti-stress and antidepressant uses. Recent studies (both in humans and laboratory animals), however, have reported that ginkgo administration does not produce significant changes in brain MAO A or MAO B, suggesting that mechanisms other than MAO inhibition need to be considered as mediating some of its antidepressant effects.(78),(79) Another study evaluated the effectiveness of ginkgo in forty depressed patients above the age of fifty who showed incomplete response to tricyclic or tetracyclic antidepressants.(80) Patients in the treated group demonstrated significantly improved outcomes in depressive symptoms when compared to the placebo group.

Of interest, is that ginkgo products may be effective in reducing antidepressant-induced sexual dysfunction in humans.(81),(82),(83) It was reported to be 84% effective in treating antidepressant-induced sexual dysfunction predominately caused by selective serotonin reuptake inhibitors.(81) The authors presumed the effectiveness was due to such pharmacological mechanisms as effects on platelet activating factor, prostaglandin inhibition, peripheral vasodilatation, and central serotonin and norepinephrine receptor factor modulation.


Ginkgo has been used in China for thousands of years in the treatment of asthma. Ginkgo, a PAF inhibitor, can inhibit inflammatory pathways that are implicated in asthmatic conditions, and has been reported beneficial in reducing antigen-induced lung anaphylaxis in laboratory animals.(84),(85) In one study, clinical symptoms and pulmonary functions of asthma patients were improved in contrast to placebo, where the ginkgo product significantly reduced airway hyper-reactivity.(86) Another in vitro study reported that ginkgolide B may have anti-inflammatory effects that are helpful in addition to other conventional therapies in controlling asthmatic patients.(87) A clinical study found that ginkgo may decrease the activation of PKCalpha in inflammatory cells and thereby decrease the IL-5 level in induced sputum, allowing ginkgo to be used in conjunction with glucocorticosteroid therapy for asthma.(108)


Ginkgo has also been reported in clinical studies to help decrease the symptoms of PMS. A standardized extract of gingko was reported useful in a placebo controlled, multicenter, double blind study in treating congestive symptoms of PMS.(88) The authors reported that the ginkgo preparation was effective against the congestive symptoms of PMS, particularly breast symptoms and emotional disturbances. Another randomized, placebo-controlled study in 85 women with PMS found that ginkgo was efficient effective at reducing the severity of symptoms.(109)

Other Uses

Ginkgo is used in a variety of clinical conditions that require an increase in blood flow, including altitude sickness,(89),(110) vertigo and other symptoms of vestibulocochlear disorders,(90),(91),(111) and sexual dysfunction.(83),(92) A small randomized trial found that the addition of ginkgo to glucocorticoid therapy for olfactory loss improved symptoms greater than drug monotherapy alone.(112)

A small placebo-controlled study found that the use of ginkgo as an adjunct to clozapine was found useful for enhancing the effect of clozapine on negative symptoms in patients with treatment-resistant schizophrenia.(113)

A small clinical study in China found that administration of ginkgo supplement to doxorubicin (Adriamycin) treatment reduced the acute cardiotoxic effects of doxorubicin.(114)

Studies using ginkgo in combination with other supplements (including L-arginine, ginseng, damiana and vitamins/minerals, ArginMax) has reported to be beneficial in treating sexual dysfunction, although a study using ginkgo alone reported no benefit over placebo.(115),(116)

A small double-blind, placebo-controlled, parallel group trial found that ginkgo improved fatigue in patients with multiple sclerosis.(117)


  1. Peter H, et al. On the Pharmacology of the Active Ingredients of Ginkgo biloba. Arzneim-Forsch/Drug Res. 1966;16(6):719-25.
  2. Victoire C, et al. Isolation of Flavonol Glycosides from Ginkgo biloba Leaves. Planta Medica. 1988;56:245-47.
  3. Major RT. The Ginkgo, the Most Ancient Living Tree. The Resistance of Ginkgo biloba L. to Pests Accounts in Part for the Longevity of This Species. Science. Sep1967;157(794):1270-3.
  4. View Abstract: Kleijnen J, et al. Ginkgo biloba for Cerebral Insufficiency. Br J Clin Pharm. 1992;34:352-58.
  5. Kleijnen J, et al. Ginkgo biloba. Lancet. 1992;340(8828):1136-39.
  6. View Abstract: Maurer K, et al. Clinical Efficacy of Ginkgo biloba Special Extract EGb 761 in Dementia of the Alzheimer Type. J Psychiatr Res. 1997;31(6):645-55.
  7. View Abstract: Kanowski S, et al. Proof of Efficacy of the Ginkgo biloba Special Extract EGb 761 in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-infarct Dementia. Pharmacopsychiatry. 1996;29:47-56.
  8. View Abstract: Meyer B. Multicenter Randomized Double-blind Drug versus Placebo Study of Ginkgo biloba Extract in the Treatment of Tinnitus. Presse Med. 1986;15:1562-64.
  9. Odawara M, et al. Ginkgo biloba. Neurology. 1997;48(3):789-90.
  10. PDR for Herbal Medicines, 2nd ed. Montvale, NJ: Medical Economics Company; 2000:344.
  11. Behrman: Nelson Textbook of Pediatrics, 16th ed. W B Saunders Company; 2000:2304.
  12. Rowin J, et al. Spontaneous Bilateral Subdural Hematomas Associated with Chronic Ginkgo biloba Ingestion. Neurology. Jun1996;46(6):1775-76.
  13. View Abstract: Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril. Mar1999;71(3):517-22.
  14. View Abstract: Lugasi A, Horvahovich P, Dworschak E. Additional Information to the In Vitro Antioxidant Activity of Ginkgo biloba L. Phytother Res. Mar1999;13(2):160-2.
  15. View Abstract: Kose L, et al. Lipoperoxidation Induced by Hydrogen Peroxide in Human Erythrocyte Membranes. 2. Comparison of the Antioxidant Effect of Ginkgo biloba Extract (EGb 761) with Those of Water-soluble and Lipid-soluble Antioxidants. J Intern Med Res. 1995;23:9-18.
  16. Marcocci L, Packer L, Drov-Lefaix MT, et al. Antioxidant Action of Ginkgo biloba Extract EGb 761. Methods Enzymol. 1994;234:462-75.
  17. View Abstract: Rong Y, Geng Z, Lau BH. Ginkgo biloba Attenuates Oxidative Stress in Macrophages and Endothelial Cells. Free Radic Biol Med. 1996;20(1):121-7.
  18. View Abstract: Ramassamy C, Averill D, Beffert U, et al. Oxidative Damage and Protection by Antioxidants in the Frontal Cortex of Alzheimer's Disease is Related to the Apolipoprotein E Genotype. Free Radic Biol Med. Sep1999;27(5-6):544-53.
  19. View Abstract: Christen Y. Oxidative Stress and Alzheimer Disease(1). Am J Clin Nutr. Feb2000;71(2 Part 2):621S-629S.
  20. View Abstract: Delanty N, Dichter MA. Antioxidant Therapy in Neurologic Disease. Arch Neurol. Sep2000;57(9):1265-70.
  21. View Abstract: Haramaki N, Aggarwal S, Kawabata T, et al. Effects of Natural Antioxidant Ginkgo biloba Extract (EGB 761) on Myocardial Ischemia-reperfusion Injury. Free Radic Biol Med. Jun1994;16(6):789-94.
  22. View Abstract: Shen JG, Zhou DY. Efficiency of Ginkgo biloba Extract (EGb 761) in Antioxidant Protection Against Myocardial Ischemia and Reperfusion Injury. Biochem Mol Biol Int. Jan1995;35(1):125-34.
  23. View Abstract: Hu B, Sun S, Mei G, Chen L, Tong E. Protective effects of Ginkgo biloba extract on rats during cerebral ischemia/reperfusion. Chin Med J (Engl). Sep2002;115(9):1316-20.
  24. View Abstract: Droy-Lefaix MT, Cluzel J, Menerath JM, et al. Antioxidant Effect of a Ginkgo biloba Extract (EGb 761) on the Retina. Int J Tissue React. 1995;17(3):93-100.
  25. View Abstract: Ritch R. Potential Role for Ginkgo biloba Extract in the Treatment of Glaucoma. Med Hypotheses. Feb2000;54(2):221-35.
  26. View Abstract: Orhan H, Marol S, Hepsen IF, et al. Effects of Some Probable Antioxidants on Selenite-induced Cataract Formation and Oxidative Stress-related Parameters in Rats. Toxicology. Dec1999;139(3):219-32.
  27. View Abstract: Lebuisson DA, et al. Treatment of Senile Macular Degeneration with Ginkgo biloba Extract. A Preliminary Double-blind Drug vs. Placebo Study. Presse Med. Sep1986;15(31):1556-58.
  28. View Abstract: Koc RK, Akdemir H, Kurtsoy A, et al. Lipid Peroxidation in Experimental Spinal Cord Injury. Comparison of Treatment with Ginkgo biloba, TRH and Methylprednisolone. Res Exp Med (Berl). 1995;195(2):117-23.
  29. View Abstract: Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba Extract (EGb 761) Protects Human Low Density Lipoproteins Against Oxidative Modification Mediated by Copper. Biochem Biophys Res Commun. Jul1995;212(2):360-6.
  30. View Abstract: Kose K, Dogan P. Lipoperoxidation Induced by Hydrogen Peroxide in Human Erythrocyte Membranes. 1. Protective Effect of Ginkgo biloba Extract (EGb 761). J Int Med Res. Jan1995;23(1):1-8.
  31. View Abstract: Pietri S, Sequin JR, d’Arbigny P, et al. Ginkgo biloba Extract (EGb 761) Pretreatment Limits Free Radical-induced Oxidative Stress in Patients Undergoing Coronary Bypass Surgery. Cardiovasc Drugs Ther. Apr1997;11(2):121-31.
  32. View Abstract: Pietri S, Maurelli E, Drieu K, et al. Cardioprotective and Anti-oxidant Effects of the Terpenoid Constituents of Ginkgo biloba Extract (EGb 761). J Mol Cell Cardiol. Feb1997;29(2):733-42.
  33. View Abstract: Ozenirler S, Dincer S, Akyol G, et al. The Protective Effect of Ginkgo biloba Extract on CCl4-induced Hepatic Damage. Acta Physiol Hung. 1997;85(3):277-85.
  34. View Abstract: Li CX, Li L, Lou J, et al. The Protective Effects of Traditional Chinese Medicine Prescription, Han-dan-gan-le, on CCl4-induced Liver Fibrosis in Rats. Am J Chin Med. 1998;26(3-4):325-32.
  35. View Abstract: Sastre J, Pallardo FV, Garcia de la Asuncion J, et al. Mitochondria, Oxidative Stress and Aging. Free Radic Res. Mar2000;32(3):189-98.
  36. View Abstract: Inselmann G, Blohmer A, Kottny W, et al. Modification of Cisplatin-induced Renal P-aminohippurate Uptake Alteration and Lipid Peroxidation by Thiols, Ginkgo biloba Extract, Deferoxamine and Torbafylline. Nephron. 1995;70(4):425-9.
  37. View Abstract: Emerit I, et al. Clastogenic Factors in the Plasma of Chernobyl Accident Recovery Workers: Anticlastogenic Effect of Ginkgo biloba Extract. Radiat Res. Nov1995;144(2):198-205.
  38. View Abstract: Barth SA, Inselmann G, Engemann R, et al. Influences of Ginkgo biloba on Cyclosporin A Induced Lipid Peroxidation in Human Liver Microsomes in Comparison to Vitamin E, Glutathione and N-acetylcysteine. Biochem Pharmacol. May1991;41(10):1521-6.
  39. Braquet P. Anti-anaphylactic Properties of BN 52021: A Potent Platelet Activating Factor Antagonist. Advances in Experimental Medicine and Biology. 1987;215:215-33.
  40. View Abstract: Smith PF, Maclennan K, Darlington CL. The Neuroprotective Properties of the Ginkgo biloba Leaf: A Review of the Possible Relationship to Platelet-activating Factor (PAF). J Ethnopharmacol. Mar1996;50(3):131-9.
  41. View Abstract: Haines DD, Bak I, Ferdinandy P, et al. Cardioprotective Effects of the Calcineurin Inhibitor FK506 and the PAF Receptor Antagonist and Free Radical Scavenger, EGb 761, in Isolated Ischemic/reperfused Rat Hearts. J Cardiovasc Pharmacol. Jan2000;35(1):37-44.
  42. View Abstract: Lagente V, Biochot E, Carre C, et al. Effects of the Platelet Activating Factor Antagonists BN 52021 and BN 50730 on Antigen-induced Bronchial Hyperresponsiveness and Eosinophil Infiltration in Lung from Sensitized Guinea-pigs. Clin Exp Allergy. Dec1993;23(12):1002-10.
  43. View Abstract: Zagrean L, Vatasescu R, Munteanu AM, et al. Preliminary EEG Study of Protective Effects of Tebonin in Transient Global Cerebral Ischemia in Rats. Rom J Physiol. Jan1998;35(1-2):161-8.
  44. View Abstract: Soybir G, Koksoy F, Ekiz F, Yalcin O, et al. The Effects of Free Oxygen Radical Scavenger and Platelet-activating Factor Antagonist Agents in Experimental Acute Pancreatitis. Pancreas. Aug1999;19(2):143-9.
  45. View Abstract: Auguet M, et al. Effects of Ginkgo biloba on Arterial Smooth Muscle Responses to Vasoactive Stimuli. Gen Pharmacol. 1982;13(2):169-71.
  46. View Abstract: Bauer U. 6-Month Double-blind Randomised Clinical Trial of Ginkgo biloba Extract Versus Placebo in Two Parallel Groups in Patients Suffering from Peripheral Arterial Insufficiency. Arzneim-Forsch/Drug Res. 1984;34(6):716-20.
  47. View Abstract: Itil TM, Eralp E, Ahmed I, et al. The Pharmacological Effects of Ginkgo biloba, a Plant Extract, on the Brain of Dementia Patients in Comparison with Tacrine. Psychopharmacol Bull. 1998;34(3):391-7.
  48. View Abstract: Bayer TA, Wirths O, Majtenyi K, et al. Key Factors in Alzheimer's Disease: Beta-amyloid Precursor Protein Processing, Metabolism and Intraneuronal Transport. Brain Pathol. Jan2001;11(1):1-11.
  49. View Abstract: Seif-El-Nasr M, El-Fattah AA. Lipid Peroxide, Phospholipids, Glutathione Levels and Superoxide Dismutase Activity in Rat Brain after Ischaemia: Effect of Ginkgo biloba Extract. Pharmacol Res. Nov1995;32(5):273-8.
  50. View Abstract: Bastianetto S, Ramassamy C, Dore S, et al. The Ginkgo biloba Extract (EGb 761) Protects Hippocampal Neurons Against Cell Death Induced by Beta-amyloid. Eur J Neurosci. Jun2000;12(6):1882-90.
  51. View Abstract: Le Bars PL, Katz MM, Berman N, et al. A Placebo-controlled, Double-blind, Randomized Trial of an Extract of Ginkgo biloba for Dementia. North American EGb Study Group. JAMA. Oct1997;278(16):1327-32.
  52. View Abstract: Van Dongen MC, van Rossum E, Kessels AG, et al. The Efficacy of Ginkgo for Elderly People with Dementia and Age-associated Memory Impairment: New Results of a Randomized Clinical Trial. J Am Geriatr Soc. Oct2000;48(10):1183-94.
  53. View Abstract: Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. Aug2002;288(7):835-40.
  54. View Abstract: Wettstein A. Cholinesterase Inhibitors and Gingko Extracts--Are They Comparable in the Treatment of Dementia? Comparison of Published Placebo-controlled Efficacy Studies of at Least Six Months' Duration. Phytomedicine. Jan2000;6(6):393-401.
  55. View Abstract: Winter JC. The Effects of An Extract of Ginkgo biloba, EGb 761, on Cognitive Behavior and Longevity in the Rat. Physiol Behav. Feb1998;63(3):425-33.
  56. View Abstract: Gajewski A, Hensch SA. Ginkgo biloba and Memory for a Maze. Psychol Rep. Apr1999;84(2):481-4.
  57. View Abstract: Cohen-Salmon C, Venault P, Martin B, et al. Effects of Ginkgo biloba Extract (EGb 761) on Learning and Possible Actions on Aging. J Physiol Paris. Dec1997;91(6):291-300.
  58. View Abstract: Hoyer S, Lannert H, Noldner M, et al. Damaged Neuronal Energy Metabolism and Behavior are Improved by Ginkgo biloba Extract (EGb 761). J Neural Transm. 1999;106(11-12):1171-88.
  59. View Abstract: Kennedy DO, Scholey AB, Wesnes KA. The Dose-dependent Cognitive Effects of Acute Administration of Ginkgo biloba to Healthy Young Volunteers. Psychopharmacology (Berl). Sep2000;151(4):416-23.
  60. View Abstract: Ramassamy C, et al. The Ginkgo biloba Extract, EGb761, Increases Synaptosomal Uptake of 5-hydroxytryptamine: In-vitro and Ex-vivo Studies. J Pharm Pharmacology. 1992;44(11):943-45.
  61. View Abstract: Mix JA, Crews WD. An Examination of the Efficacy of Ginkgo biloba Extract EGb761 on the Neuropsychologic Functioning of Cognitively Intact Older Adults. J Altern Complement Med. Jun2000;6(3):219-29.
  62. View Abstract: Wesnes KA, Ward T, McGinty A, et al. The Memory Enhancing Effects of a Ginkgo biloba/Panax ginseng Combination in Healthy Middle-aged Volunteers. Psychopharmacology (Berl). Nov2000;152(4):353-61.
  63. View Abstract: Mouren X, Caillard P, Schwartz F. Study of the Antiischemic Action of EGb 761 in the Treatment of Peripheral Arterial Occlusive Disease by TcPo2 Determination. Angiology. Jun1994;45(6):413-7.
  64. View Abstract: Ernst E. Ginkgo biloba in the Treatment of Intermittent Claudication. A Critical Review. Fortschritte der Medizin. 1996;114(8):85-87.
  65. View Abstract: Drabaek H, Peterson JR, Winberg N, et al. The Effect of Ginkgo biloba Extract in Patients with Intermittent Claudication. Ugeskr Laeger. Jul1996;158(27):3928-31.
  66. View Abstract: Blume J, Kieser M, Holscher U. Placebo-controlled Double-blind Study of the Effectiveness of Ginkgo biloba Special Extract EGb 761 in Trained Patients with Intermittent Claudication. Vasa. 1996;25(3):265-74.
  67. View Abstract: De Felice M, Gallo P, Masotti G. Current Therapy of Peripheral Obstructive Arterial Disease. The Non-surgical Approach. Angiology. 1990;41:1-11.
  68. View Abstract: Pittler MH, Ernst E. Ginkgo biloba Extract for the Treatment of Intermittent Claudication: A Meta-analysis of Randomized Trials. Am J Med. Mar2000;108(4):276-81.
  69. View Abstract: Peters H, Kieser M, Holscher U. Demonstration of the Efficacy of Ginkgo biloba Special Extract EGb 761 on Intermittent Claudication--A Placebo-controlled, Double-blind Multicenter Trial. Vasa. May1998;27(2):06-10.
  70. View Abstract: Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med. 2002;7(4):265-7.
  71. View Abstract: Jastreboff PJ, Zhou S, Jastreboff MM, et al. Attenuation of Salicylate-induced Tinnitus by Ginkgo biloba Extract in Rats. Audiol Neurootol. Jul1997;2(4):197-212.
  72. View Abstract: Hoffmann F, Beck C, Schutz A, et al. Ginkgo Extract EGb 761 (Tenobin)/HAES Versus Naftidrofuryl (Dusodril)/HAES. A Randomized Study of Therapy of Sudden Deafness. Laryngorhinootologie. Mar1994;73(3):149-52.
  73. View Abstract: Holgers KM, Axelsson A, Pringle I. Ginkgo biloba Extract for the Treatment of Tinnitus. Audiology. Mar1994;33(2):85-92.
  74. View Abstract: Drew S, Davies E. Effectiveness of Ginkgo biloba in Treating Tinnitus: Double blind, Placebo Controlled Trial. BMJ. Jan2001;322(7278):73.
  75. View Abstract: Meyer B. A Multicenter Study of Tinnitus. Epidemiology and Therapy. Ann Otolaryngol Chir Cervicofac 1986;103(3):185-8.
  76. View Abstract: Eckmann F. Cerebral Insufficiency--treatment with Ginkgo-biloba Extract. Time of Onset of Effect in a Double-blind Study with 60 Inpatients. Fortschr Med. Oct1990;108(29):557-60.
  77. View Abstract: White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba Leaves Inhibit Monoamine Oxidase. Life Sci. 1996;58(16):1315-21.
  78. View Abstract: Porsolt RD, Roux S, Drieu K. Evaluation of a Ginkgo biloba Extract (EGb 761) in Functional Tests for Monoamine Oxidase Inhibition. Arzneimittelforschung. Mar2000;50(3):232-5.
  79. View Abstract: Fowler JS, Wang GJ, Volkow ND, et al. Evidence that Gingko biloba Extract Does not Inhibit MAO A and B in Living Human Brain. Life Sci. Jan2000;66(9):PL141-6.
  80. Schubert H, et al. Depressive Episode Primarily Unresponsive to Therapy in Elderly Patients: Efficacy of Ginkgo biloba extract (EGb 761) in Combination with Antidepressants. Geriatr Forsch. 1993;3:45–53.
  81. View Abstract: Cohen AJ, et al. Ginkgo biloba for Antidepressant-induced Sexual Dysfunction. J Sex Marital Ther. 1998;24(2):139-43.
  82. Sikora R, et al. Ginkgo biloba Extract in the Therapy of Erectile Dysfunction. J Urol. 1989;141:188A.
  83. Ashton AK, Ahrens K, Gupta S, et al. Antidepressant-induced Sexual Dysfunction and Ginkgo Biloba. Am J Psychiatry. May2000;157(5):836-7.
  84. View Abstract: Braquet P, et al. Ethnopharmacology and the Development of Natural PAF Antagonists as Therapeutic Agents. J Ethnopharmacol. Apr1991;32(1-3):135-39.
  85. View Abstract: Touvay C, et al. Inhibition of Antigen-induced Lung Anaphylaxis in the Guinea-pig by BN 52021 a New specific PAF-acether Receptor Antagonist Isolated from Ginkgo biloba. Agents Actions. Jan1986;17(3-4): 371-72.
  86. View Abstract: Li MH, Zhang HL, Yang BY. Effects of Ginkgo Leave Concentrated Oral Liquor in Treating Asthma. Zhongguo Zhong Xi Yi Jie He Za Zhi. Apr1997;17(4):216-8.
  87. View Abstract: Mahmoud F, Abul H, Onadeko B, et al. In Vitro Effects of Ginkgolide B on Lymphocyte Activation in Atopic Asthma: Comparison with Cyclosporin A. Jpn J Pharmacol. Jul2000;83(3):241-5.
  88. View Abstract: Tamborini A, Taurelle R. Value of Standardized Ginkgo biloba Extract (EGb 761) in the Management of Congestive Symptoms of Premenstrual Syndrome. Rev Fr Gynecol Obstet. Jul1993;88(7-9):447-57.
  89. View Abstract: Dumont L, Mardirosoff C, Tramer MR. Efficacy and Harm of Pharmacological Prevention of Acute Mountain Sickness: Quantitative Systematic Review. BMJ. Jul2000;321(7256):267-72.
  90. View Abstract: Cesarani A, Meloni F, Alpini D, et al. Ginkgo biloba (EGb 761) in the Treatment of Equilibrium Disorders. Adv Ther. Sep1998;15(5):291-304.
  91. View Abstract: Haguenauer JP, Cantenot F, Koskas H, et al. [Treatment of Equilibrium Disorders with Ginkgo biloba Extract. A Multicenter Double-blind Drug vs. Placebo Study]. Presse Med. Sep1986;15(31):1569-72.
  92. Ellison JM, DeLuca P. Fluoxetine-induced Genital Anesthesia Relieved by Ginkgo biloba Extract. J Clin Psychiatry. Apr1998;59(4):199-200.
  93. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61(15):2163-2175. Review.
  94. Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of ginkgo (Ginkgo biloba) during pregnancy and lactation. Can J Clin Pharmacol. Fall 2006;13(3):e277-e284. Epub 2006 Nov 3. Review.
  95. Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci. 15 Aug 2009;283(1-2):224-229. Epub 2009 Mar 14.
  96. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 21 Jan 2009;(1):CD003120. Review.
  97. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 19 Nov 2008;300(19):2253-2262. Erratum in: JAMA. 17Dec2008;300(23):2730.
  98. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 6 May 2008;70(19 Pt 2):1809-1817. Epub 2008 Feb 27.
  99. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 23 Dec 2009;302(24):2663-2670.
  100. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R; GINDON Study Group. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. Mar 2009;13(2):183-190.
  101. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol. 3 Jul 2007;7:30.
  102. Kennedy DO, Jackson PA, Haskell CF, Scholey AB. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Hum Psychopharmacol. Dec 2007;22(8):559-566.
  103. Kaschel R. Ginkgo biloba: specificity of neuropsychological improvement--a selective review in search of differential effects. Hum Psychopharmacol. Jul 2009;24(5):345-370. Review.
  104. Kennedy DO, Haskell CF, Mauri PL, Scholey AB. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. Hum Psychopharmacol. Jun 2007;22(4):199-210.
  105. Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev. Jul-Aug 2008;28(4):258-265.
  106. Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Teijink JA. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 15 Apr 2009;(2):CD006888. Review.
  107. Li XS, Zheng WY, Lou SX, Lu XW, Ye SH. Effect of Ginkgo leaf extract on vascular endothelial function in patients with early stage diabetic nephropathy. Chin J Integr Med. Feb 2009;15(1):26-29. Epub 7 Mar 2009.
  108. Tang Y, Xu Y, Xiong S, et al. The effect of Ginkgo biloba extract on the expression of PKCalpha in the inflammatory cells and the level of IL-5 in induced sputum of asthmatic patients. J Huazhong Univ Sci Technolog Med Sci. Aug 2007;27(4):375-380.
  109. Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med. Aug 2009;15(8):845-8.
  110. Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med. Winter2007;18(4):251-257. Erratum in: Wilderness Environ Med. Spring 2008;19(1):51.
  111. Hamann KF. [Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations] HNO. Apr 2007;55(4):258-263. Review. German.
  112. Seo BS, Lee HJ, Mo JH, Lee CH, Rhee CS, Kim JW. Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray. Arch Otolaryngol Head Neck Surg. Oct 2009;135(10):1000-1004.
  113. Doruk A, Uzun O, Ozşahin A. A placebo-controlled study of extract of Ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. Jul 2008;23(4):223-227.
  114. Yi SY, Nan KJ, Chen SJ, et al. [Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer] Zhongguo Zhong Xi Yi Jie He Za Zhi. Jan 2008;28(1):68-70. Chinese.
  115. Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J Sex Marital Ther. Oct-Dec 2006;32(5):369-378.
  116. Meston CM, Rellini AH, Telch MJ. Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav. Aug 2008;37(4):530-547. Epub 15 Feb 2008.
  117. Johnson SK, Diamond BJ, Rausch S, Kaufman M, Shiflett SC, Graves L. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY). Jan 2006;2(1):19-24.